Dupilumab Sales Forecast, and Market Size Analysis - 2034

Key Factors Driving Dupilumab Growth

1) Massive existing revenue base with continued strong growth

Dupixent is already one of the world’s largest biologics, which significantly de-risks future growth. According to Sanofi and Regeneron Pharmaceuticals, global Dupixent sales reached €10.7 billion (~$11.9 billion) in 2023, representing roughly 31% YoY growth. In Q2 2025 alone, global sales reached $4.34 billion, up 22% YoY, indicating continued momentum despite its large base.

This scale creates strong operating leverage and reinforces physician familiarity across specialties.

2) COPD approval opened a major new blockbuster market

This is currently one of Dupilumab’s biggest growth drivers. In September 2024, the FDA approved Dupixent as the first biologic for COPD, followed by approvals in the EU, China, and Japan in 2025.

Key Phase III BOREAS/NOTUS data showed:

• ~30% reduction in annualized moderate/severe COPD exacerbations
• Improved lung function
• Reduced hospitalization risk

Sanofi estimated approximately 300,000 eligible COPD patients in the U.S. alone, while BMO analysts projected ~$2.9 billion peak COPD sales by 2030.

3) Broad multi-indication diversification reduces reliance on one disease

Dupixent is approved across multiple large indications including:

• Atopic dermatitis
• Asthma
• Chronic rhinosinusitis with nasal polyps (CRSwNP)
• Eosinophilic esophagitis (EoE)
• Prurigo nodularis
• Chronic spontaneous urticaria (approved in U.S. in April 2025)
• COPD

The April 2025 CSU approval alone added another meaningful patient pool, with >300,000 symptomatic US patients who remain uncontrolled despite antihistamines.

This diversification protects Dupixent from single-indication competitive pressure.

4) Strong superiority data vs competitors improves market share retention

In June 2025, Dupixent showed superiority vs Xolair in the Phase IV EVEREST trial in patients with CRSwNP and coexisting asthma.

Dupixent outperformed Xolair across:

• Nasal polyp reduction
• Sense of smell improvement
• Lung function improvement
• Asthma control endpoints

These head-to-head wins strengthen payer negotiations and physician confidence.

Dupilumab Recent Developments

In April 2026, The US Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of children aged two to 11 years with chronic spontaneous urticaria (CSU) who remain symptomatic despite histamine-1 antihistamine (H1AH) treatment. This expands the previous approval for Dupixent in adults and adolescents aged 12 years and older with CSU.  
“Dupilumab Sales Forecast, and Market Size Analysis - 2034” report provides comprehensive insights of Dupilumab for potential indication like Asthma and Atopic dermatitis in the 7MM. A detailed picture of Dupilumab’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the Dupilumab for potential indications. The Dupilumab market report provides insights about Dupilumab’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Dupilumab performance, future market assessments inclusive of the Dupilumab market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Dupilumab sales forecasts, along with factors driving its market.

Dupilumab Drug Summary

Dupilumab is a fully human monoclonal antibody developed by Regeneron Pharmaceuticals and Sanofi that inhibits signaling of both Interleukin-4 and Interleukin-13 by binding to the IL-4 receptor alpha subunit (IL-4Rα). By blocking these central drivers of type 2 inflammation, dupilumab reduces inflammatory responses across multiple allergic and eosinophilic diseases. It is administered via subcutaneous injection and is approved for a broad range of indications, including moderate-to-severe Atopic Dermatitis, Asthma, Chronic Rhinosinusitis with Nasal Polyps, Eosinophilic Esophagitis, and Prurigo Nodularis, with continued expansion into additional inflammatory conditions. Owing to its strong efficacy, broad label expansion, and blockbuster commercial performance, Dupilumab has become one of the leading biologics in immunology and respiratory medicine. The report provides Dupilumab’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Dupilumab Market Report

The report provides insights into:

• A comprehensive product overview including the Dupilumab MoA, description, dosage and administration, research and development activities in potential indication like Asthma and Atopic dermatitis.
• Elaborated details on Dupilumab regulatory milestones and other development activities have been provided in Dupilumab market report.
• The report also highlights Dupilumab‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The Dupilumab market report also covers the patents information, generic entry and impact on cost cut.
• The Dupilumab market report contains current and forecasted Dupilumab sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Dupilumab market report also features the SWOT analysis with analyst views for Dupilumab in potential indications.

Methodology

The Dupilumab market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Dupilumab Analytical Perspective

• In-depth Dupilumab Market Assessment

This Dupilumab sales market forecast report provides a detailed market assessment of Dupilumab for potential indication like Asthma and Atopic dermatitis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Dupilumab sales data uptil 2034.

• Dupilumab Clinical Assessment

The Dupilumab market report provides the clinical trials information of Dupilumab for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Dupilumab Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Dupilumab Market Potential & Revenue Forecast

• Projected market size for the Dupilumab and its key indications
• Estimated Dupilumab sales potential (Dupilumab peak sales forecasts)
• Dupilumab Pricing strategies and reimbursement landscape

Dupilumab Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Dupilumab Market positioning compared to existing treatments
• Dupilumab Strengths & weaknesses relative to competitors

Dupilumab Regulatory & Commercial Milestones

• Dupilumab Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Dupilumab Clinical Differentiation

• Dupilumab Efficacy & safety advantages over existing drugs
• Dupilumab Unique selling points

Dupilumab Market Report Highlights

• In the coming years, the Dupilumab market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Dupilumab companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Dupilumab’s dominance.
• Other emerging products for Asthma and Atopic dermatitis are expected to give tough market competition to Dupilumab and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Dupilumab in potential indications.
• Analyse Dupilumab cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Dupilumab sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Dupilumab in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of Dupilumab? How strong is Dupilumab’s clinical and commercial performance?
• What is Dupilumab’s clinical trial status in each individual indications such as Asthma and Atopic dermatitis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Dupilumab Manufacturers?
• What are the key designations that have been granted to Dupilumab for potential indications? How are they going to impact Dupilumab’s penetration in various geographies?
• What is the current and forecasted Dupilumab market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Dupilumab in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Dupilumab for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is Dupilumab? What is the duration of therapy and what are the geographical variations in cost per patient?

This product will be delivered within 2 business days.